Currently Viewing:
Newsroom
Currently Reading
Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds
January 20, 2018 – Laura Joszt
Study Finds Prior Authorization Mandates for PCSK9 Drugs Raise Questions of Access
January 19, 2018 – Mary Caffrey
Long-Term Oral Contraceptive Use Associated With Reduced Risk of Ovarian, Endometrial Cancer
January 19, 2018 – Jaime Rosenberg
This Week in Managed Care: January 19, 2018
January 19, 2018
Wearable Biosensors Have No Significant Impact on Clinical Outcomes
January 19, 2018 – Kaitlynn Ely
Proposed Drug to Treat Oculopharyngeal Muscular Dystrophy Gains Orphan Drug Designation
January 19, 2018 – Kelly Davio
What We're Reading: House Passes CHIP Funding; Cancer Blood Test; Drug Policy Office Budget
January 19, 2018 – AJMC Staff
AJMC® in the Press, January 19, 2018
January 19, 2018 – AJMC Staff
Risk-Targeted Lung Cancer Screening Shows Modest Benefits
January 19, 2018 – Samantha DiGrande

Excess Cardiovascular Risk in RA Patients Has Declined Since 2000, Study Finds

Alison Rodriguez
New results from a meta-analysis reveal a decrease in the excess risk of cardiovascular events in patients with rheumatoid arthritis (RA) since the start of the 21st century.
New results from a meta-analysis reveal a decrease in the excess risk of cardiovascular events in patients with rheumatoid arthritis (RA) since the start of the 21st century.

Patients with RA are often associated with having a greater risk of cardiovascular disease, stroke, myocardial infarction (MI), congestive heart failure (CHF), and cardiovascular mortality (CVM) when compared to the general population. However, the results of the new analysis revealed that the risk of cardiovascular events is declining. The findings were presented at the Annual European Congress of Rheumatology in Madrid, Spain, according to a press release.

“This reduction in cardiovascular risk may have two explanations,” said study author Elisabeth Filhol, a rheumatologist in training at Nîmes University Hospital in France, in the statement. "It may simply be due to better management of cardiovascular risk in patients with RA.”

Researchers performed a detailed literature search to measure the changes in cardiovascular risk in this population before and after 2000. The study considered 5714 screened references; however, only 28 studies met the necessary criteria to determine the risks of cardiovascular events.

“However, knowing that systemic inflammation is the cornerstone of both RA and atherosclerosis, it may also be related to better control of chronic systemic inflammation as the result of new therapeutic strategies,” suggested senior investigator Professor Cécile Gaujoux-Viala of the University of Montpellier and head of the rheumatology department at the Nîmes University Hospital.

A meta-analysis was used to determine the relative risk for RA patients compared to a control group both before and after the start of the 21st century. The results for the studies before 2000 confirmed an increased risk for all 4 cardiovascular events in RA patients, while the studies after 2000 did not demonstrate an association between CHF and CVM. There was an increased risk of MI, but it was lower than in the period before 2000.

“Over the past fifteen years, new treatment strategies such as tight control, treat to target, methotrexate optimisation, and the use of biologic DMARDs has allowed a better control of systemic inflammation in patients with RA,” Gaujoux-Viala concluded.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!